News Features World-wise: As In-Person Meetings Resume, Global Voices Hope to Be Heard Shelley Wood December 13, 2021
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward Todd Neale November 16, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Daily News Higher CV Mortality Among More Socially Vulnerable US Adults Yael L. Maxwell October 20, 2021
News Daily News HF Care Didn’t Suffer as Clinicians Turned to Telehealth in COVID-19 Caitlin E. Cox October 13, 2021
News Daily News In Adults, CV Pathology Dominates COVID-19 Multisystem Inflammatory Syndrome Shelley Wood September 23, 2021
News Conference News AHA Announces Fully Virtual Meeting in Light of Surging COVID-19 Numbers Michael O'Riordan September 17, 2021
News Daily News From Excess Amputations to Postpregnancy HF, Studies Shine Light on Racial Divide L.A. McKeown September 06, 2021
News Conference News ESC 2021 In HFrEF, AI Shows Promise For Predicting Beta Blocker Response Yael L. Maxwell September 03, 2021
News Conference News ESC 2021 AV Junction Ablation Plus CRT Cuts Deaths in Permanent AF Subset Todd Neale September 01, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021